MidWestOne Financial Group Inc. Grows Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MidWestOne Financial Group Inc. lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 10.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,347 shares of the specialty pharmaceutical company's stock after buying an additional 2,284 shares during the quarter. MidWestOne Financial Group Inc.'s holdings in Jazz Pharmaceuticals were worth $2,998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $25,000. Quadrant Capital Group LLC lifted its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP boosted its stake in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after buying an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth $28,000. Finally, Allianz SE bought a new position in Jazz Pharmaceuticals in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $111.02 on Wednesday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market cap of $6.84 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. The company's 50 day simple moving average is $114.74 and its 200-day simple moving average is $122.01. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. During the same quarter last year, the business earned $2.68 earnings per share. The business's quarterly revenue was down .5% on a year-over-year basis. As a group, equities analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Seamus Mulligan bought 1,621 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average price of $103.00 per share, with a total value of $166,963.00. Following the purchase, the director now owns 101,621 shares of the company's stock, valued at $10,466,963. This trade represents a 1.62% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company's stock, valued at $4,826,778.66. The trade was a 10.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,236 shares of company stock valued at $3,956,190. 4.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JAZZ. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Royal Bank of Canada lowered their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Barclays restated an "overweight" rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, Piper Sandler reiterated an "overweight" rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.